- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer ; volume:18 ; number:5 ; day:5 ; month:8 ; year:2023 ; pages:793-800 ; date:9.2023
Targeted oncology ; 18, Heft 5 (5.8.2023), 793-800, 9.2023
- Urheber
-
Lee, Arnold
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-023-00984-4
- URN
-
urn:nbn:de:101:1-2023121213090894623336
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Arnold
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients